Clinical trial · Interventional
Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer
Liquid Biopsies (blood, Gastric Fluid) for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer: a Pilot Project
NCT04253106CI-TRIAL-00080971LISA-HDGCcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Activating somatic mutations and methylation profiles identified by liquid biopsies could identify CDH1 and CTNNA1 pathogenic variants carriers with invasive diffuse gastric cancer undetectable by upper G-I endoscopy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hereditary Diffuse Gastric Cancer | Hereditary Gastric Diffuse Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liquid biopsies (blood, gastric fluid). | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Unaffected carriers of constitutional mutations
- description
- Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
- interventionNames
- Genetic: Liquid biopsies (blood, gastric fluid).
- type
- ACTIVE_COMPARATOR
- label
- All patients with FOGD
- description
- without observation of macroscopic lesions paired with cases (age and sex)
- interventionNames
- Genetic: Liquid biopsies (blood, gastric fluid).
Primary outcomes (1)
- measure
- Number of subjects in whom somatic mutations or methylation profiles are detected.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Case: * Patient ≥ 18 years old * CDH1 or CTNNA1 germline pathogenic variant. * No history of diffuse gastric cancer. * French social security. * Ability to understand and willingness to sign a written informed consent document. Volunteers: * Patients ≥ 18 years old * Patients with no oncological history * Patients with macroscopically normal oeso-gastroduodenal fibroscopy * French social security. * Ability to understand and willingness to sign a written informed consent Exclusion Criteria: for both arms * Patients with cancer being treated * Patients with metastatic cancer * Medical contraindication to general anesthesia or FOGD (bleeding disorder, pregnant women ) * Patients under guardianship or curator
References
Publications (0)
Data not yet available
No reference posted for this study.